These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 27342497)
1. [Expression of CD30 in Diffuse Large B Cell Lymphoma and Its Clinical Significance]. Zhao YF; Qian SX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):717-21. PubMed ID: 27342497 [TBL] [Abstract][Full Text] [Related]
2. [Expression of CD30 in Patients with Diffuse Large B-Cell Lymphoma and Clinical Significance]. Qu Y; Lu XZ; Wang RX; Hei XF; Li J; Xiao BT; Jia ZX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):450-457. PubMed ID: 38660851 [TBL] [Abstract][Full Text] [Related]
3. [Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma]. Wang KL; Chen C; Shi PF; Yu JH; Tan JF; Qian SX; Gao DQ; Chen K; Liu LR; Xie YP; Xu Y Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1079-1085. PubMed ID: 30111411 [TBL] [Abstract][Full Text] [Related]
4. [Expression and clinical significance of Ki-67 in diffuse large B cell lymphoma]. Zhou Y; Zhao Y; Bo J; Li YF; Ma C; Shi YN Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1162-6. PubMed ID: 24156426 [TBL] [Abstract][Full Text] [Related]
5. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma]. Wen JJ; Liu ZB; Xu J; Xu CG Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791 [TBL] [Abstract][Full Text] [Related]
6. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma]. Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230 [TBL] [Abstract][Full Text] [Related]
7. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma]. Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773 [No Abstract] [Full Text] [Related]
8. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110 [TBL] [Abstract][Full Text] [Related]
9. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma]. Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579 [No Abstract] [Full Text] [Related]
11. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites. Wang C; Li W; Liu C; He H; Bai O Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654 [TBL] [Abstract][Full Text] [Related]
12. [Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma]. Fu ZY; Zhu J; Song YQ; Liu WP; Ji XQ; Zhan SY Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Jun; 46(3):405-11. PubMed ID: 24943019 [TBL] [Abstract][Full Text] [Related]
13. [A retrospective analysis of clinical characteristics and prognostic factors for 124 cases of primary gastric lymphomas]. He Y; Wang L; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Cao L; Fan L; Li JY; Xu W Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):505-510. PubMed ID: 28655094 [No Abstract] [Full Text] [Related]
14. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience. Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406 [TBL] [Abstract][Full Text] [Related]
15. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224 [TBL] [Abstract][Full Text] [Related]
16. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Slack GW; Steidl C; Sehn LH; Gascoyne RD Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752 [TBL] [Abstract][Full Text] [Related]
17. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma]. Wen J; Zhou J; Liu Z; Liu T; Xu C Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020 [TBL] [Abstract][Full Text] [Related]
18. [Expression and clinical significance of CD40 in diffuse large B-cell lymphoma]. Wang S; Wang YP; Hao YY; Zheng Y Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):819-23. PubMed ID: 24507100 [TBL] [Abstract][Full Text] [Related]
19. [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma]. Zhao SX; Han Y; Zhu Q; Wang Q; Zhang WJ; Chen XC; Sun AN; Jin ZM; Qiu HY; Tang XW; Fu ZZ; He GS; Miao M; Ma X; Wu DP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):623-7. PubMed ID: 23815910 [TBL] [Abstract][Full Text] [Related]
20. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]